Zobrazeno 1 - 10
of 487
pro vyhledávání: '"David M. O'Malley"'
Autor:
Ramez N. Eskander, Kathleen N. Moore, Bradley J. Monk, Thomas J. Herzog, Christina M. Annunziata, David M. O’Malley, Robert L. Coleman
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The definition of “platinum-resistant ovarian cancer” has evolved; it now also reflects cancers for which platinum treatment is no longer an option. Standard of care for platinum-resistant ovarian cancer is single-agent, non-platinum chemotherapy
Externí odkaz:
https://doaj.org/article/358e10443d3f428898b57cc9d3f7a136
Autor:
Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O'Malley, Ursula Matulonis, Gottfried E. Konecny
Publikováno v:
Gynecologic Oncology Reports, Vol 47, Iss , Pp 101155- (2023)
Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube,
Externí odkaz:
https://doaj.org/article/7bbfec9715e24a6da26bff5934edd4e9
Autor:
Monica D. Levine, David M. O'Malley, Paulina J. Haight, Leigha Senter, Vincent Wagner, Kristin L. Bixel, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Eric M. McLaughlin, Floor J. Backes
Publikováno v:
Gynecologic Oncology Reports, Vol 46, Iss , Pp 101173- (2023)
Objective: To determine the recurrence rate and survival among early-stage epithelial ovarian cancer cases considering homologous recombination deficiency (HRD) status. Methods: Single institution retrospective study of stage I/II EOC patients from 2
Externí odkaz:
https://doaj.org/article/bfd62de4649446d5876e8b0e7bf137d0
Publikováno v:
Gynecologic Oncology Reports, Vol 46, Iss , Pp 101171- (2023)
Effective second-line treatment options for patients with recurrent ovarian clear cell carcinoma (OCCC) are limited. This case series sought to report tumor characteristics and oncologic outcomes in a small group of patients treated with combination
Externí odkaz:
https://doaj.org/article/d57dfa7fe6364a51b6e4df6ddc7cbfcf
Autor:
Rachael N. Piver, Vincent M. Wagner, Monica D. Levine, Floor J. Backes, Laura J. Chambers, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Christa I. Nagel, David M. O'Malley, Kristin L. Bixel
Publikováno v:
Gynecologic Oncology Reports, Vol 46, Iss , Pp 101156- (2023)
Objective: Gynecologic cancers are associated with a high risk of venous thromboembolism (VTE). The Khorana score is a validated tool to assess risk of VTE in cancer patients. The purpose of this study is to determine if the Khorana score can be used
Externí odkaz:
https://doaj.org/article/8bbfeabd1daa4b9e845502c906bb652a
Autor:
Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7162-7173 (2021)
Abstract Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum‐based chemotherapy and baseline disease. Methods Patients were randomized 2:1 to rec
Externí odkaz:
https://doaj.org/article/2cbcf9c399a94021b6832bbcf96e807d
Autor:
Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven, Elena I. Braicu, Amnon Amit, Andrés Redondo, Ruchit Shah, Nehemiah Kebede, Carol Hawkes, Divya Gupta, Tatia Woodward, David M. O’Malley, Antonio González-Martín
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: The PRIMA phase 3 trial showed niraparib significantly prolongs median progression-free survival (PFS) versus placebo in patients with advanced ovarian cancer (OC) responsive to first-line platinum-based chemotherapy, including those who
Externí odkaz:
https://doaj.org/article/9ca988f600544d9cb14a5db3e3ba0a1c
Autor:
Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 c
Externí odkaz:
https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda3
Autor:
Glenn P. Boyles, MD, Ashlee M. Weaver, MD, David E. Cohn, MD, Floor J. Backes, MD, Larry J. Copeland, MD, Kristin L. Bixel, MD, Jeffrey M. Fowler, MD, David M. O'Malley, MD, Casey M. Cosgrove, MD
Publikováno v:
AJOG Global Reports, Vol 1, Iss 4, Pp 100022- (2021)
BACKGROUND: There is a paucity of literature regarding the outcomes following vulvar excision for nonmalignant lesions. This is a common procedure among gynecologists and gynecologic oncologists, and a body of evidence is warranted to guide clinical
Externí odkaz:
https://doaj.org/article/f57c139424c749ec9c35a0f3f9c75843
Publikováno v:
Gynecologic Oncology Reports, Vol 33, Iss , Pp 100599- (2020)
Externí odkaz:
https://doaj.org/article/1f10dbb7263446cf9efaf3381d6394f0